Skysona Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited treatment options for CALD, advances in gene-editing technologies, increasing rare disease diagnosis rates, expansion of orphan drug development programs, early success of stem cell-based therapies.

The growth in the forecast period can be attributed to increasing approvals of gene therapies, rising investment in rare disease pipelines, growing adoption of personalized medicine, expansion of advanced therapy manufacturing capacity, increasing long-term outcome monitoring frameworks. Major trends in the forecast period include increasing adoption of gene therapy for rare diseases, growing use of autologous stem cell modification, expansion of one-time curative treatment models, rising focus on pediatric genetic disorders, enhanced regulatory support for advanced therapies.

The increase in the prevalence of rare diseases is expected to drive the growth of the Skysona market in the future. Rare diseases are medical conditions that affect a small proportion of the population, and their increasing prevalence is attributed to factors such as improved diagnostic techniques, better awareness among healthcare professionals, and advancements in genetic testing. Skysona is particularly useful for treating rare diseases, especially cerebral adrenoleukodystrophy (CALD), by offering a gene therapy approach that addresses the genetic mutation causing the disease. This treatment potentially improves neurological outcomes and extends survival in affected children. For example, in August 2024, ALD Info, a Netherlands-based community-driven initiative, reported that the incidence of adrenoleukodystrophy (ALD) is around 1 in 17,000 newborns. A male newborn has a 35-40% risk of developing cerebral ALD between ages 3 and 18, though it can also manifest in adulthood. Therefore, the rising prevalence of rare diseases is expected to drive the Skysona market forward.

Major companies operating in the Skysona market are focusing on technological advancements, such as regulatory-driven safety label optimization, to gain a competitive edge. This process involves updating clinical and safety information based on real-world evidence and regulatory feedback to refine patient eligibility and risk management. For instance, in August 2025, Bluebird Bio, a U.S.-based biotechnology company, introduced revised labeling for SKYSONA (elivaldogene autotemcel) after FDA review. The update includes a boxed warning for hematologic malignancy risk, restricts use to CALD patients without a suitable HLA-matched stem cell donor, and mandates enhanced long-term monitoring. This change improves patient safety, aligns treatment with the latest risk data, and strengthens post-marketing surveillance, though it may limit the eligible patient pool.

In September 2023, Bluebird Bio revised its agreement with Lonza Group AG to enhance manufacturing capabilities. This collaboration aims to support the production of Bluebird Bio’s gene therapies, including Zynteglo and Skysona, ensuring scalable, high-quality manufacturing processes to meet increasing demand and accelerate the delivery of these innovative treatments for rare diseases, such as thalassemia and CALD. Lonza Group AG, a Switzerland-based contract manufacturing organization, plays a key role in manufacturing Skysona.

Major companies operating in the skysona market are Bluebird bio Inc.

North America was the largest region in the skysona market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the skysona market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the skysona market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the skysona market by increasing costs of imported viral vectors, cell processing equipment, biomanufacturing consumables, and cryopreservation logistics used in gene therapy production. North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces higher barriers in advanced therapy manufacturing expansion. These tariffs are elevating therapy development and delivery costs for rare disease treatments. However, they are also encouraging domestic gene therapy manufacturing, regional vector production, and investment in localized advanced therapy infrastructure.

The skysona market research report is one of a series of new reports that provides skysona market statistics, including skysona industry global market size, regional shares, competitors with a skysona market share, detailed skysona market segments, market trends and opportunities, and any further data you may need to thrive in the skysona industry. This skysona market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Skysona refers to a gene therapy designed to slow the progression of cerebral adrenoleukodystrophy (CALD), a rare genetic disorder affecting the nervous system in young boys. The mechanism of action involves using a patient's own stem cells, which are modified to produce a functional version of the ABCD1 gene, responsible for producing an enzyme that helps break down fatty acids.

The main indication of skysona include cerebral adrenoleukodystrophy (CALD). Cerebral adrenoleukodystrophy (CALD) refers to a rare, genetic neurodegenerative disorder that primarily affects boys and is characterized by the progressive loss of brain function due to the buildup of very long-chain fatty acids in the nervous system. The various formulations involve intravenous infusion. The several patient demographics include pediatric patients and adult patients and are distributed through multiple channels such as hospitals, specialty clinics, and online pharmacies. The various end-user includes academic and research institutes, biopharmaceutical companies, and patient advocacy groups.

The skysona market consists of sales of infusion bags, with the dose based on patient weight. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.